Welcome to our dedicated page for Chinook Therapeutics news (Ticker: KDNY), a resource for investors and traders seeking the latest updates and insights on Chinook Therapeutics stock.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) delivers innovative therapies for kidney diseases through its precision medicine pipeline. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives shaping the future of nephrology care.
Access real-time information about phase 3 trials for atrasentan in IgA nephropathy, progress updates on zigakibart's BEYOND study, and early-stage developments of CHK-336 for hyperoxalurias. Our curated news collection includes FDA communications, partnership announcements, and peer-reviewed research findings directly impacting therapeutic advancements.
Stay informed about key events through verified press releases and objective analysis of trial data. Content is organized to highlight material developments in proteinuria reduction therapies, kidney function preservation strategies, and novel treatment mechanisms validated by single-cell RNA sequencing insights.
Bookmark this page for streamlined access to Chinook's latest scientific achievements and corporate updates. Regular monitoring ensures you never miss critical information about one of biotech's most focused kidney disease innovators.
Chinook Therapeutics (NASDAQ: KDNY) has appointed Eric Bjerkholt as Chief Financial Officer, enhancing its leadership as it prepares for upcoming clinical trials. Bjerkholt brings over 30 years of experience in finance and operations in the biopharmaceutical sector, previously serving as CFO at Aimmune Therapeutics, where he oversaw a $2.6 billion acquisition. The company is advancing its product pipeline, focusing on treatments for kidney diseases, including the phase 3 ALIGN trial for atrasentan and BION-1301 for IgA nephropathy, signaling strong growth potential.
Chinook Therapeutics (NASDAQ: KDNY) announced its Q3 2020 financial results and business developments following its merger with Aduro Biotech on October 5th. The company has approximately $290 million in cash and marketable securities to advance its kidney disease pipeline. Chinook plans to initiate multiple clinical trials in 2021, including the phase 3 ALIGN trial for atrasentan and a phase 1 trial for CHK-336. The firm presented preclinical data, underscoring its commitment to innovative therapies for severe kidney conditions.
Chinook Therapeutics (NASDAQ: KDNY) recently announced significant presentations at ASN’s Kidney Week 2020, highlighting their clinical programs targeting kidney diseases. Key presentations included the phase 3 ALIGN trial for atrasentan in IgA nephropathy, and phase 1 data for BION-1301. Notably, the introduction of CHK-336, a potential first-in-class oral LDHA inhibitor for primary hyperoxaluria, was featured. The company aims to lead in precision kidney therapeutics and plans to initiate pivotal trials soon.
Chinook Therapeutics, a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol KDNY, announced presentations at ASN's Kidney Week 2020 from October 22-25, 2020.
The company will present clinical data on atrasentan and BION-1301 for IgA Nephropathy, with a focus on a Phase 1 study of CHK-366, a novel LDH inhibitor for primary hyperoxaluria, set to start in H2 2021. An investor call is scheduled for October 22, 2020, to discuss these developments.
FAQ
What is the market cap of Chinook Therapeutics (KDNY)?
